| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 424B3 |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV-1 molecular glue degrader |
| 10 Nov 2026 | SCHEDULE 13D/A |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure
Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader |
| 04 Nov 2026 | 424B3 |
| 04 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2026, by and among Evommune, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an... |
| 15 Oct 2026 |
Form 4: Pena Luis C., Director
Received 1,115 shares as a grant or award ($7.83K) |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Evommune Corporate Presentation September 2026 © Evommune, Inc. |
| 09 Sep 2026 | 424B3 |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
‑ Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 424B3 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology |
Loading...